Hanna Sahlin

Hanna Sahlin

Auto-generated profile, based on publicly available information

Hanna Sahlin

Centre for Psychiatry Research, Department of Clinical Neuroscience Karolinska Institute, & Stockholm Health Care Services, Region Stockholm Stockholm Sweden

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2015 in Journal of Psychopathology and Behavioral Assessment
Verified
Journal Article
Closed access
PDF file
JBJohan Bjureberg
Johan Bjureberg
BLBrjánn Ljótsson
Brjánn Ljótsson
MTMatthew T. Tull
Matthew T. Tull
EHErik Hedman
Erik Hedman
HSHanna Sahlin
Hanna Sahlin
KGKim L. Gratz
Kim L. Gratz

11 October 2018 in BMC Psychiatry
Verified
Journal Article
Open access
PDF file
JBJohan Bjureberg
Johan Bjureberg
HSHanna Sahlin
Hanna Sahlin
EHErik Hedman-Lagerlöf
Erik Hedman-Lagerlöf
KGKim L. Gratz
Kim L. Gratz
MTMatthew T. Tull
Matthew T. Tull
BLBrjánn Ljótsson
Brjánn Ljótsson
Nonsuicidal self-injury (NSSI) is common among adolescents and associated with negative outcomes. However, treatments developed specifically for NSSI and the proposed NSSI disorder (NSSID) are scarce, and access to empirically supported treatments for NSSI in many areas is limited. Online treatments carry the potential to increase the availability of evidence-based treatments. Emotion regulation individual therapy for adolescents (ERITA) has shown promise in the treatment of adolescents with NSSID. The present study examined the feasibility, acceptability, and utility of an online version of ERITA. Twenty-five adolescents (aged 13–17) with NSSID and their parents were included in an uncontrolled open trial. Self-report and clinician-rated assessments of outcomes such as NSSI, self-destructive behaviors, emotion dysregulation, and global functioning were administered at pre-treatment, post-treatment, 3- and 6- month follow-up. Measures of NSSI, self-destructive behaviors, and emotion dysregulation were also assessed weekly during treatment. Ratings of treatment credibility, expectancy, and satisfaction were acceptable, and the therapeutic alliance and treatment completion rate (96%) were high. Adolescent participation in the treatment was associated with a statistically significant increase in past-month NSSI abstinence (p = .007), large-sized improvements in past-month NSSI frequency (55% reduction, 95% confidence interval [CI]: 29, 72; Cohen’s d = 0.88, 95% CI: 0.73, 1.06) and global functioning (d = 1.01, 95% CI: 0.77, 1.32), and medium-sized improvements in emotion dysregulation (d = 0.75, 95% CI: 0.59, 0.90) and NSSI versatility (d = 0.63, 95% CI: 0.54, 0.77) from pre- to post-treatment. These improvements were further strengthened at 3-month follow-up and maintained at 6-month follow-up. The online therapist-guided parent program was associated with small- to large-sized (ds = 0.47–1.22) improvements in adaptive parent behaviors, and these improvements were maintained or further improved upon at 6-month follow-up. Moreover, in line with the theoretical model underlying ERITA, change in emotion dysregulation mediated changes in both NSSI frequency and self-destructive behaviors over the course of treatment. Together, results suggest that online ERITA is an acceptable, feasible, and promising low-intensity treatment for adolescents with NSSID. The results of this open trial must be replicated in controlled studies. ClinicalTrials.gov ( NCT02697019 ). Registered 2 March 2016

1 October 2019 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Open access
MLMaria Lalouni
Maria Lalouni
BLBrjánn Ljótsson
Brjánn Ljótsson
MBMarianne Bonnert
Marianne Bonnert
RSRichard Ssegonja
Richard Ssegonja
MBMarc Benninga
Marc Benninga
OOOla Olén
Ola Olén
Scalable and effective treatments are needed for children with functional abdominal pain disorders (FAPDs). We performed a randomized controlled trial of the efficacy and cost effectiveness of cognitive behavioral therapy delivered online (Internet-CBT) compared with usual therapy. We studied children (age, 8-12 y) diagnosed with FAPDs, based on the Rome IV criteria, in Sweden from September 2016 through April 2017. The patients were assigned randomly to groups that received 10 weeks of therapist-guided, internet-delivered cognitive behavioral therapy (Internet-CBT, n = 46) or treatment as usual (treatments within the health care and school systems, including medications and visits to doctors and other health care professionals; n = 44). The primary outcome was global child-rated gastrointestinal symptom severity assessed using the Pediatric Quality of Life Gastrointestinal Symptom scale. All outcomes were collected from September 2016 through January 2018. Secondary outcomes included quality of life, gastrointestinal-specific anxiety, avoidance behaviors, and parental responses to children's symptoms. Societal costs and costs for health care consumption were collected during the treatment. Children who received Internet-CBT had a significantly larger improvement in gastrointestinal symptom severity with a medium effect size (Cohen's d = 0.46; 95% CI, 0.05-0.88; number needed to treat, 3.8) compared with children who received the treatment as usual. The children's quality of life, gastrointestinal-specific anxiety, avoidance behaviors, and parental responses to children's symptoms also improved significantly in the Internet-CBT group compared with the treatment as usual group. The effects of Internet-CBT persisted through 36 weeks of follow-up evaluation. Children who received Internet-CBT had significantly less health care use than children who received treatment as usual, with an average cost difference of US $137 (P = .011). We calculated a cost savings of US $1050 for every child treated with Internet-CBT compared with treatment as usual. In a randomized trial of pediatric patients with FAPDs, we found Internet-CBT to be clinically cost effective compared with treatment as usual. Internet-CBT has the potential to increase the availability of treatment for a number of patients and reduce health care costs. ClinicalTrials.gov: NCT02873078.

1 June 2017 in JAMA Psychiatry
Verified
Journal Article
Open access
PDF file
HSHanna Sahlin
Hanna Sahlin
RKRalf Kuja-Halkola
Ralf Kuja-Halkola
JBJohan Bjureberg
Johan Bjureberg
PLPaul Lichtenstein
Paul Lichtenstein
YMYasmina Molero
Yasmina Molero
CHClara Hellner
Clara Hellner
Nonfatal deliberate self-harm (DSH) is the act of inflicting harm on oneself through the ingestion of harmful substances or causing tissue damage (eg, cutting or burning oneself).1 Although most epidemiologic research in this area has focused on DSH as a risk factor for completed suicide,2-5 the term also includes self-harming acts performed without suicidal intent (eg, behaviors aimed at regulating an intense negative state).6-8 Typically, DSH debuts between the ages of 12 and 14 years, and it is increasingly being recognized as a serious global health problem9-11 and as a risk factor for future attempted or completed suicide5 and for the development of psychiatric disorders, substance abuse, and antisocial behavior.12-14

28 December 2017 in BMC Psychiatry
Verified
Journal Article
Open access
PDF file
JBJohan Bjureberg
Johan Bjureberg
HSHanna Sahlin
Hanna Sahlin
CHClara Hellner
Clara Hellner
EHErik Hedman-Lagerlöf
Erik Hedman-Lagerlöf
KGKim L. Gratz
Kim L. Gratz
BLBrjánn Ljótsson
Brjánn Ljótsson
Nonsuicidal self-injury (NSSI) is a serious health risk behavior that forms the basis of a tentative diagnosis in DSM-5, NSSI Disorder (NSSID). To date, established treatments specific to NSSI or NSSID are scarce. As a first step in evaluating the feasibility, acceptability, and utility of a novel treatment for adolescents with NSSID, we conducted an open trial of emotion regulation individual therapy for adolescents (ERITA): a 12-week, behavioral treatment aimed at directly targeting both NSSI and its proposed underlying mechanism of emotion regulation difficulties. Seventeen girls (aged 13–17; mean = 15.31) with NSSID were enrolled in a study adopting an uncontrolled open trial design with self-report and clinician-rated assessments of NSSI and other self-destructive behaviors, emotion regulation difficulties, borderline personality features, and global functioning administered at pre-treatment, post-treatment, and 6-month follow-up. Measures of NSSI and emotion regulation difficulties were also administered weekly during treatment. Ratings of treatment credibility and expectancy and the treatment completion rate (88%) were satisfactory, and both therapeutic alliance and treatment attendance were strong. Intent-to-treat analyses revealed significant improvements associated with large effect sizes in past-month NSSI frequency, emotion regulation difficulties, self-destructive behaviors, and global functioning, as well as a medium effect size in past-month NSSI versatility, from pre- to post-treatment. Further, all of these improvements were either maintained or further improved upon at 6-month follow-up. Finally, change in emotion regulation difficulties mediated improvements in NSSI over the course of treatment. Results suggest the acceptability, feasibility, and utility of this treatment for adolescents with NSSID. ClinicalTrials.gov (NCT02326012, December 22, 2014, retrospectively registered).

18 March 2022 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
ATAshley E. Tate
Ashley E. Tate
HSHanna Sahlin
Hanna Sahlin
SLShengxin Liu
Shengxin Liu
YLYi Lu
Yi Lu
SLSebastian Lundström
Sebastian Lundström
RKRalf Kuja-Halkola
Ralf Kuja-Halkola
In one of the largest, most comprehensive studies on borderline personality disorder (BPD) to date, this article places into context associations between this diagnosis and (1) 16 different psychiatric disorders, (2) eight somatic illnesses, and (3) six trauma and adverse behaviors, e.g., violent crime victimization and self-harm. Second, it examines the sex differences in individuals with BPD and their siblings. A total of 1,969,839 Swedish individuals were identified from national registers. Cumulative incidence with 95% confidence intervals (CI) was evaluated after 5 years of follow-up from BPD diagnosis and compared with a matched cohort. Associations were estimated as hazard ratios (HR) with 95% CIs from Cox regression. 12,175 individuals were diagnosed with BPD (85.3% female). Individuals diagnosed with BPD had higher cumulative incidences and HRs for nearly all analyzed indicators, especially psychiatric disorders. Anxiety disorders were most common (cumulative incidence 95% CI 33.13% [31.48–34.73]). Other notable findings from Cox regressions include psychotic disorders (HR 95% CI 24.48 [23.14–25.90]), epilepsy (3.38 [3.08–3.70]), violent crime victimization (7.65 [7.25–8.06]), and self-harm (17.72 [17.27–18.19]). HRs in males and females with BPD had overlapping CIs for nearly all indicators. This indicates that a BPD diagnosis is a marker of vulnerability for negative events and poor physical and mental health similarly for both males and females. Having a sibling with BPD was associated with an increased risk for psychiatric disorders, trauma, and adverse behaviors but not somatic disorders. Clinical implications include the need for increased support for patients with BPD navigating the health care system.